S Kirk

2.0k total citations
12 papers, 336 citations indexed

About

S Kirk is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S Kirk has authored 12 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Surgery, 5 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S Kirk's work include HER2/EGFR in Cancer Research (4 papers), Sarcoma Diagnosis and Treatment (3 papers) and Testicular diseases and treatments (3 papers). S Kirk is often cited by papers focused on HER2/EGFR in Cancer Research (4 papers), Sarcoma Diagnosis and Treatment (3 papers) and Testicular diseases and treatments (3 papers). S Kirk collaborates with scholars based in United Kingdom, Spain and Germany. S Kirk's co-authors include Jennifer Eng‐Wong, Andreas Schneeweiß, Maeve Waldron-Lynch, Tamas Hickish, Javier Cortés, Alexandru Eniu, Vernon Harvey, Stephen Chia, Gordon Rustin and Robert Huddart and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

S Kirk

11 papers receiving 333 citations

Peers

S Kirk

ONCOL

PRM

SURGE

RNMI

Suryanarayan V.S. Deo India

Ayşe Durnalı Türkiye

Michelle Leviov Israel

Birthe Heitkötter Germany

Andri Papakonstantinou Sweden

Emma J. Groen Netherlands

Ghislaine Sierankowski France

Claudia Mosillo Italy

C Brambilla France

Zoltán Szöllősi Hungary

Suryanarayan V.S. Deo India

S Kirk

259 ×1.2

ONCOL

72 ×0.5

183 ×1.8

PRM

38 ×0.5

SURGE

55 ×0.7

RNMI

Citations per year, relative to S Kirk S Kirk (= 1×) peers Suryanarayan V.S. Deo

Countries citing papers authored by S Kirk

Since Specialization

Citations

This map shows the geographic impact of S Kirk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Kirk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Kirk more than expected).

Fields of papers citing papers by S Kirk

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Kirk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Kirk. The network helps show where S Kirk may publish in the future.

Co-authorship network of co-authors of S Kirk

This figure shows the co-authorship network connecting the top 25 collaborators of S Kirk. A scholar is included among the top collaborators of S Kirk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Kirk. S Kirk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Topp, Max S., Monica Tani, Michael Dickinson, et al.. (2025). 280 | GLOFITAMAB COMBINED WITH R‐CHOP OR POLA‐R‐CHP IN PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B‐CELL LYMPHOMA: FINAL RESULTS FROM THE NP40126 STUDY. Hematological Oncology. 43(S3). 1 indexed citations

Davis, David, Jo Wray, Paul Gough, et al.. (2025). “What witchcraft is this?”: Paramedics report gains in productivity, well-being, and patient flow from piloting ambient voice technology in an NHS Ambulance Service. medRxiv.

Bradshaw, Daniel, Stephen Bremner, Sumita Verma, et al.. (2023). Hepmarc: A 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. PLoS ONE. 18(7). e0288598–e0288598. 4 indexed citations

Schneeweiß, Andreas, Stephen Chia, Tamas Hickish, et al.. (2017). Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European Journal of Cancer. 89. 27–35. 165 indexed citations

Bianchini, Giampaolo, Astrid Kiermaier, Giulia Bianchi, et al.. (2017). Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Research. 19(1). 16–16. 76 indexed citations

Schneeweiß, Andreas, Tamas Hickish, V. Harvey, et al.. (2017). Abstract P4-21-02: Pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: Efficacy analysis of a phase II cardiac safety study (TRYPHAENA). Cancer Research. 77(4_Supplement). P4–21. 2 indexed citations

Cortés, Javier, Karen A. Gelmon, P. Fumoleau, et al.. (2008). Phase II evaluation of the efficacy and safety of trastuzumab plus pertuzumab therapy in patients with HER2-positive metastatic breast cancer that had progressed during trastuzumab treatment. European Journal of Cancer Supplements. 6(7). 217–217. 1 indexed citations

Huddart, Robert, Michael O’Doherty, Anwar R. Padhani, et al.. (2007). ¹⁸ Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group. Journal of Clinical Oncology. 25(21). 3090–3095. 68 indexed citations

Mead, Graham M., Gordon Rustin, Sally Stenning, et al.. (2006). Medical Research Council trial of 2 versus 5 CT scans in the surveillance of patients with stage I non-seminomatous germ cell tumours of the testis. Journal of Clinical Oncology. 24(18_suppl). 4519–4519. 3 indexed citations

10.

Huddart, Robert, M. J. OʼDoherty, Anwar R. Padhani, et al.. (2006). A prospective study of ¹⁸FDG PET in the prediction of relapse in patients with high risk clinical stage I (CS1) non-seminomatous germ cell cancer (NSGCT): MRC study TE22. Journal of Clinical Oncology. 24(18_suppl). 4520–4520. 3 indexed citations

11.

Dolan, Stephen A., et al.. (1999). Initial experience with breast reconstruction using the transverse rectus abdominis myocutaneous flap: a study of 45 patients.. PubMed. 68(1). 22–6. 6 indexed citations

12.

Kirk, S, et al.. (1990). Does preoperative computed tomography scanning aid assessment of oesophageal carcinoma?. Postgraduate Medical Journal. 66(773). 191–194. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact